Search clinical trials for: BI 655075

Total 1216 results

Boehringer Ingelheim

Completed

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Lupus Nephritis

Spain, United Kingdom, United States, Canada, Thailand, Germany, Italy, Japan, Serbia, Australia, Korea, Republic of, Mexico, Malaysia, Philippines, Poland, Portugal, Greece, Hong Kong, Czechia, France
Boehringer Ingelheim

Completed

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Hemorrhage

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers

Healthy

Belgium
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers

Healthy

Germany
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Healthy | Arthritis, Rheumatoid

Germany, Netherlands, New Zealand, Poland, Spain, Czechia
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
Boehringer Ingelheim

Completed

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Lupus Nephritis

United Kingdom, Thailand, Germany, Japan, United States, Australia, Korea, Republic of, Hong Kong, Poland, Greece, Mexico, Czechia, Canada, Malaysia, Philippines, Portugal
Boehringer Ingelheim

Completed

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan, Korea, Republic of
AbbVie
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Asthma

United States, Korea, Republic of, Belgium, Taiwan, Canada, Germany, United Kingdom, France, Netherlands, Poland
AbbVie

Completed

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Healthy

Belgium
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Pulmonary Arterial Hypertension | Cardiovascular Disease+Pulmonary Disease

United Kingdom
Boehringer Ingelheim

Completed

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Psoriasis

United States, Canada, Finland, France, Germany, Norway, Sweden
AbbVie
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Healthy

Japan, Korea, Republic of
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Ankylosing Spondylitis (AS)
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie
Boehringer Ingelheim

Completed

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic
AbbVie
Boehringer Ingelheim

Completed

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Belgium, Canada, Germany, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom
AbbVie

Completed

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Puerto Rico
AbbVie

Enrolling by invitation

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie
Boehringer Ingelheim

Completed

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn Disease
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
AbbVie

Completed

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Psoriasis

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany

3

Subscribe